Company / Shareholders' Equity
BIOCRYST PHARMACEUTICALS INC Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$119.2M
FY2025
5-year range
-$475.9M / -$107.0M
FY2021-FY2025
Trend
+75.0%
vs FY2024
Sector context
#200 of 213
Health Care
What the data says
BIOCRYST PHARMACEUTICALS INC reports negative total equity of -$119M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$119M in FY2025.
Improved from -$456M to -$119M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 213This company -$119.2M Sector average $2.5B
▼
-104.7% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity increased 75.0% year-over-year.
- Ranks #200 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2017.
- Lowest shareholders' equity in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$119.2M | +75.0% |
| FY2024 | -$475.9M | -4.5% |
| FY2023 | -$455.5M | -54.6% |
| FY2022 | -$294.6M | -175.4% |
| FY2021 | -$107.0M | -455.4% |
| FY2020 | -$19.3M | -150.4% |
| FY2019 | $38.3M | -22.3% |
| FY2018 | $49.2M | -41.2% |
| FY2017 | $83.8M | +5208.4% |
| FY2016 | $1.6M | -96.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026